NorthWest Biotherapeutics Inc (NWBO)

[Lykiri]

Meirluc,

Look at the patients who got surgery between 18 and 24 months at the time of the analysis:

IMO,

44 patients got surgery, probably 41 treatment and 3 placebo.

40 patients of this group of 44 still alive at the time of the analysis. (March 2017 and look at Sentiment OS Curve)

Of this group:

21 methylated + still alive. Probably not one of the meth+ has died at the time of the analysis.(21 patients = 47.7% of 44 patients)

18 methylated- still alive at the time of the analysis.(18 patients = 40.9% of 44 patients)

1 unknown still alive at the time of the analysis.(2.2%)

Don’t worry!
Do you know another group of 44 patients with Glioblastoma Grade IV who do better?

Publication:

"MGMT status and extent of resection
In patients with methylated MGMT (n=131), mOS was
34.7 months from surgery (95% CI 27.0–40.7), with 2 and
3-year survival rates of 66.7% and 46.4%, respectively. In
patients with unmethylated MGMT (n=162), mOS was
19.8 months from surgery (95% CI 17.9–21.7), with 2 and
3-year survival rates of 32.1%, and 11.0%, respectively.